PACS Group (PACS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
4 Aug, 2026Executive summary
Achieved $1.43B in Q2 2026 revenue, up 9.1% year-over-year, with adjusted EBITDA rising 24.6% to $166.8M and net income up 49.8% to $76.3M; diluted EPS increased 51.6% to $0.47.
Closed acquisition of an Alaska senior living facility and three Nevada properties for $104.3M, and 20 Texas skilled nursing facilities from Eduro, with 14 more expected to close in Q3/Q4 2026.
Operates 324–344 facilities across 17 states, serving over 31,900 patients daily with ~48,000 employees as of June 30, 2026.
Growth driven by acquiring underperforming facilities and converting them to higher-acuity, value-add transitional care.
83.6% of SNFs achieved a 4 or 5 star CMS Quality Measure rating; mature facilities averaged 4.5 stars and 93.8% occupancy.
Financial highlights
Q2 2026 revenue: $1.43B (up 9.1% YoY); adjusted EBITDA: $166.8M (up 24.6% YoY); adjusted EPS: $0.63 (up 34.0% YoY); net income: $76.3M (up 49.8% YoY); adjusted net income: $101.7M.
Operating income for Q2 2026 was $109.3M, up 35.8% year-over-year.
Cash and available liquidity: $756.6M as of June 30, 2026, including $164.5M in cash; no outstanding balance on the $600M credit facility.
LTM revenue: $5.55B; LTM adjusted EBITDA: $610.7M.
Total assets stood at $5.66B, with total equity of $1.12B as of June 30, 2026.
Outlook and guidance
2026 annual revenue guidance: $5.75B–$5.85B, ~10% growth over 2025; adjusted EBITDA guidance: $640M–$660M, ~29% growth over 2025.
Guidance includes partial-year contribution from 20 Texas facilities acquired from Eduro; excludes remaining Eduro facilities and future acquisitions.
Management expects current cash balances and cash flow from operations to cover operating needs for at least the next 12 months.
Latest events from PACS Group
- Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 20248 Jul 2026 - Board elections, auditor ratification, and executive pay all approved without stockholder questions.PACS
AGM 202610 Jun 2026 - Q1 2026 revenue up 11.2%, net income up 184%, and EBITDA guidance raised to $605–$625M.PACS
Q1 202618 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.PACS
Proxy filing28 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PACS
Proxy filing28 Apr 2026 - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 202527 Feb 2026 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Offering 2.78M shares at $39.67 to repay debt; founders retain control; strong growth, high regulatory risk.PACS
Registration Filing29 Nov 2025